IL-6 blockade in systemic juvenile idiopathic arthritis: achievement of inactive disease and remission (data from the German AID-registry)
Systemic juvenile idiopathic arthritis (sJIA) is a complex disease with an autoinflammatory component of unknown etiology related to the innate immune system. A major role in the pathogenesis has been ascribed to proinflammatory cytokines like interleukin-6 (IL-6), and effective drugs inhibiting the...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
05 April 2018
|
| In: |
Pediatric rheumatology
Year: 2018, Volume: 16 |
| ISSN: | 1546-0096 |
| DOI: | 10.1186/s12969-018-0236-y |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s12969-018-0236-y
|
| Author Notes: | M. Bielak, E. Husmann, N. Weyandt, J.-P. Haas, B. Hügle, G. Horneff, U. Neudorf, T. Lutz, E. Lilienthal, T. Kallinich, K. Tenbrock, R. Berendes, T. Niehues, H. Wittkowski, E. Weißbarth-Riedel, G. Heubner, P. Oommen, J. Klotsche, Dirk Foell and E. Lainka |
| Summary: | Systemic juvenile idiopathic arthritis (sJIA) is a complex disease with an autoinflammatory component of unknown etiology related to the innate immune system. A major role in the pathogenesis has been ascribed to proinflammatory cytokines like interleukin-6 (IL-6), and effective drugs inhibiting their signaling are being developed. This study evaluates sJIA patients treated with the IL-6 inhibitor tocilizumab (TCZ) concerning clinical response rate, disease course and adverse effects in a real-life clinical setting. |
|---|---|
| Item Description: | Gesehen am 20.08.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1546-0096 |
| DOI: | 10.1186/s12969-018-0236-y |